Labcorp (LH) Stock Forecast & Price Target

Labcorp
Bull Case

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

• Laboratory Co. of America Holdings recently announced the acquisition of MLM Medical Labs, a move that establishes the company as the only central laboratory provider with a wholly owned laboratory network across four continents. This strategic expansion significantly enhances its global capabilities in biomarker testing for clinical trials, positioning the company to capture a larger share of the growing pharmaceutical and biotech testing market.
• The company has issued a long-term outlook through 2029 that projects compound annual revenue growth of 5% to 8% and adjusted earnings per share growth of 8.5% to 11.5%. This guidance suggests a sustained period of expansion beyond the current fiscal year, providing investors with a clear framework for potential earnings acceleration and long-term value creation.
• Laboratory Co. of America Holdings has reaffirmed its 2026 guidance for adjusted earnings per share of $18.10 to $18.55, which aligns closely with the analyst consensus of $18.32. This consistency in financial forecasting supports confidence in the company's near-term earnings visibility and its ability to meet investor expectations for profitability.
• The stock is currently trading at $315.26, which is below the average analyst price target of $336.36. With a consensus rating of "Moderate Buy" from nine analysts, the current valuation may present an opportunity for investors to enter the position before the stock potentially reaches its projected fair value.
• Institutional investors have shown strong confidence in the company, with 95.94% of the stock owned by institutions and hedge funds. Recent filings show significant increases in holdings by major players such as Squarepoint Ops LLC and Baird Financial Group Inc., indicating that professional investors are actively accumulating shares in anticipation of future growth.